Squarepoint
VRAX icon

Squarepoint’s Virax Biolabs VRAX Stock Holding History

Squarepoint’s Portfolio VRAX Stock Details VRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,625
Closed -$78.8K – 5544
2024
Q3 		$78.8K Buy
+1,625
New +$93.4K ﹤0.01% 3921

Other funds holding VRAX

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
RS
R Squared Central, Hong Kong $182M AUM 18.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northwestern Mutual Wealth Management
Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Squarepoint's VRAX Position: Q4 2024 in Review

Squarepoint sold out of Virax Biolabs (VRAX) in Q4 2024, closing a stake of 1,625 shares — an estimated $78.8K sold.

Squarepoint first reported a position in VRAX in Q3 2024 and held it in 1 quarter. The position peaked at $78.8K in Q3 2024. 6 funds tracked by Wall St. Rank hold VRAX as of Q4 2024.

  • Squarepoint reported no remaining Virax Biolabs position as of Q4 2024 after selling out during the quarter.
  • Squarepoint sold 1,625 Virax Biolabs shares in Q4 2024, an estimated $78.8K.
  • Squarepoint first reported a position in Virax Biolabs in Q3 2024 and held it in 1 quarter.
  • Squarepoint's Virax Biolabs position peaked at $78.8K in Q3 2024.
  • 6 funds tracked by Wall St. Rank held Virax Biolabs as of Q4 2024.

Based on Squarepoint's 13F filing for Q4 2024, filed 14 Feb 2025.